Stock Market: Morgan Stanley Bets on Top 4 Indian Pharmaceutical Firms, Sun Pharma and Cipla on the List

Stock Market Investment: Morgan Stanley, a well-known worldwide broking firm, recently identified four important Indian pharmaceutical companies in its investigation. Sun Pharma has an overweight rating and a target price of Rs 1960/share. The broking identifies the company’s excellent pipeline of specialty pharmaceuticals, strategic emphasis on chronic therapeutics, and strong financial sheet as major differentiators. Sun Pharma’s stock price has increased by about 6.8% in the last year. Lupin has received an equal weight rating and a target price of Rs 2096. While the firm anticipates growth in the Indian market by May 2026, it also warns that increased competition in the United States may pose issues. Lupin’s stock has increased by a modest 5% in the past year.

Indian Pharma Companies Set to Surge in 2026

Morgan Stanley’s research also includes Dr. Reddy’s Laboratories and Cipla, which both received equal weight ratings. Dr. Reddy’s has set a target price of Rs 1298, citing growing demand for semaglutide. However, 2026 is likely to be a transition year for both companies. Despite recent increases in the pharmaceutical sector, investors should speak with a skilled financial advisor before investing in pharma companies, as market dynamics and foreign rivalry will continue to be important factors in future performance.